DexCom stock snapshot and recent performance DexCom (DXCM) has been drawing attention after recent price moves, with the ...

It has had strong momentum since November, but there is still plenty of upside left.

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

Dexcom achieved FY25 revenues of around $4.66bn, corresponding to a 16% uplift over FY24.

DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed ...

DexCom, Inc. DXCM reported strong preliminary results for the fourth quarter and full-year 2025. Despite the robust ...

DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full-year 2025 revenue of roughly US$4.66 billion, both rising at double-digit ...

At long last, Dexcom's Share app, which allows users to view and share data from their G5 continuous glucose monitors, will be available for Android users. The Android app just now received FDA ...